Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Gilead Sciences Inc. (NASDAQ:GILD)

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Beginner level

Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).

Historical Valuation Ratios (Summary)

Gilead Sciences Inc., historical price multiples (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Price to earnings (P/E) 641.48 59.19 — 19.58 16.45 30.72 13.61 14.26 15.26 57.34 45.72 24.66 22.75 8.24 7.85 6.92 6.83 — — —
Price to operating profit (P/OP) 19.38 29.86 — 21.83 20.66 19.07 9.61 10.14 10.15 9.74 9.58 6.83 7.45 6.02 5.82 5.22 5.23 — — —
Price to sales (P/S) 3.24 3.29 3.95 4.34 4.00 3.76 3.69 3.84 3.84 4.17 4.43 3.52 4.10 3.54 3.42 3.05 3.08 — — —
Price to book value (P/BV) 4.33 4.30 4.79 4.40 3.93 4.02 3.58 3.83 3.89 3.98 4.66 4.15 5.15 3.85 4.23 4.28 4.88 5.78 6.83 8.42

Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Gilead Sciences Inc.’s P/S ratio decreased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. Gilead Sciences Inc.’s P/BV ratio decreased from Q2 2020 to Q3 2020 but then slightly increased from Q3 2020 to Q4 2020.

Price to Earnings (P/E)

Gilead Sciences Inc., historical P/E calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
No. shares of common stock outstanding1 1,256,593,156 1,253,528,149 1,253,724,370 1,254,373,400 1,263,636,656 1,265,145,612 1,266,455,481 1,271,554,672 1,275,510,558 1,293,619,612 1,296,340,593 1,300,260,832 1,309,967,781 1,306,268,996 1,305,926,217 1,306,728,398 1,307,066,900 1,317,456,071 1,319,658,489 1,331,821,506
Selected Financial Data (US$)
Net income (loss) attributable to Gilead (in millions) 1,551  360  (3,339) 1,551  2,696  (1,165) 1,880  1,975  3  2,097  1,817  1,538  (3,865) 2,718  3,073  2,702  3,108  3,330  3,497  3,566 
Earnings per share (EPS)2 0.10 1.01 -0.20 3.96 4.26 2.13 4.70 4.63 4.28 1.23 1.70 2.66 3.53 8.88 9.35 9.67 10.33 0.00 0.00 0.00
Share price1, 3 62.79 59.87 68.81 77.47 70.10 65.39 63.98 66.07 65.28 70.35 77.87 65.69 80.36 73.21 73.44 66.92 70.50 74.00 80.41 84.68
Valuation Ratio
P/E ratio4 641.48 59.19 — 19.58 16.45 30.72 13.61 14.26 15.26 57.34 45.72 24.66 22.75 8.24 7.85 6.92 6.83 — — —
Benchmarks
P/E Ratio, Competitors5
Abbott Laboratories 48.49 58.45 58.36 45.61 41.83 44.92 53.17 52.98 56.47 136.66 122.73 213.07 220.29 45.00 73.04 50.48 55.16 — — —
AbbVie Inc. 40.17 22.60 23.92 14.70 17.82 37.29 23.42 21.71 20.60 17.29 22.09 24.91 35.47 22.56 17.16 16.90 16.54 — — —
Amgen Inc. 18.82 17.25 19.97 17.70 17.07 15.53 14.06 13.30 14.01 55.79 52.69 52.13 64.06 15.67 15.70 15.16 16.03 — — —
Bristol-Myers Squibb Co. — — — 144.77 41.99 16.53 11.97 14.51 16.81 56.09 251.38 92.56 103.55 23.59 19.40 18.96 20.56 — — —
Eli Lilly & Co. 31.95 22.54 25.59 26.56 16.19 13.31 13.84 18.38 39.13 249.24 — 79.88 — 41.51 37.39 41.29 32.39 — — —
Illumina Inc. 109.92 66.98 74.93 47.73 43.43 43.91 46.92 54.25 52.00 62.22 73.58 59.94 44.63 38.26 38.75 36.92 52.01 — — —
Johnson & Johnson 28.92 22.51 25.68 23.06 25.99 24.03 21.50 25.68 23.74 243.48 256.64 271.47 268.10 23.75 21.91 20.12 20.08 — — —
Merck & Co. Inc. 26.72 17.67 19.70 19.18 20.60 22.67 23.07 23.97 33.46 56.97 132.14 96.71 61.63 53.20 33.41 39.83 46.14 — — —
Pfizer Inc. 19.62 23.29 15.01 13.00 11.63 12.60 16.12 19.69 21.58 10.64 10.66 9.43 9.99 21.39 23.88 27.02 28.10 — — —
Regeneron Pharmaceuticals Inc. 15.09 19.91 22.27 28.35 19.86 17.03 15.94 14.56 18.17 21.53 26.96 22.09 28.99 34.90 43.35 47.93 42.64 — — —
Vertex Pharmaceuticals Inc. 20.18 20.14 34.05 43.74 52.90 23.44 20.80 20.51 22.59 65.41 108.21 175.96 155.08 193.19 149.56 166.15 — — — —
Zoetis Inc. 48.25 48.84 47.41 37.05 45.89 39.46 42.08 35.57 28.68 38.90 39.51 39.53 44.09 35.00 33.42 33.79 31.63 — — —

Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).

1 Data adjusted for splits and stock dividends.

2 Q4 2020 Calculation
EPS = (Net income (loss) attributable to GileadQ4 2020 + Net income (loss) attributable to GileadQ3 2020 + Net income (loss) attributable to GileadQ2 2020 + Net income (loss) attributable to GileadQ1 2020) ÷ No. shares of common stock outstanding
= (1,551,000,000 + 360,000,000 + -3,339,000,000 + 1,551,000,000) ÷ 1,256,593,156 = 0.10

3 Closing price as at the filing date of Gilead Sciences Inc.’s Quarterly or Annual Report.

4 Q4 2020 Calculation
P/E ratio = Share price ÷ EPS
= 62.79 ÷ 0.10 = 641.48

5 Click competitor name to see calculations.

Price to Operating Profit (P/OP)

Gilead Sciences Inc., historical P/OP calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
No. shares of common stock outstanding1 1,256,593,156 1,253,528,149 1,253,724,370 1,254,373,400 1,263,636,656 1,265,145,612 1,266,455,481 1,271,554,672 1,275,510,558 1,293,619,612 1,296,340,593 1,300,260,832 1,309,967,781 1,306,268,996 1,305,926,217 1,306,728,398 1,307,066,900 1,317,456,071 1,319,658,489 1,331,821,506
Selected Financial Data (US$)
Income (loss) from operations (in millions) 2,651  2,001  (2,983) 2,402  1,093  (1,473) 2,430  2,237  1,144  2,623  2,280  2,153  2,291  3,812  4,254  3,767  4,045  4,399  4,538  4,651 
Operating profit per share2 3.24 2.00 -0.77 3.55 3.39 3.43 6.66 6.51 6.43 7.23 8.13 9.62 10.78 12.16 12.61 12.82 13.49 0.00 0.00 0.00
Share price1, 3 62.79 59.87 68.81 77.47 70.10 65.39 63.98 66.07 65.28 70.35 77.87 65.69 80.36 73.21 73.44 66.92 70.50 74.00 80.41 84.68
Valuation Ratio
P/OP ratio4 19.38 29.86 — 21.83 20.66 19.07 9.61 10.14 10.15 9.74 9.58 6.83 7.45 6.02 5.82 5.22 5.23 — — —
Benchmarks
P/OP Ratio, Competitors5
Abbott Laboratories 40.69 45.82 45.19 35.87 34.03 34.32 37.50 36.74 36.64 38.12 38.00 39.99 60.88 47.72 41.32 30.85 24.25 — — —
AbbVie Inc. 16.32 14.42 15.23 9.13 10.82 18.43 13.53 17.93 18.35 12.32 14.01 15.78 19.63 14.77 11.57 11.19 10.49 — — —
Amgen Inc. 14.96 13.82 15.84 14.22 13.84 12.52 11.35 10.73 11.46 12.13 12.16 11.45 12.71 12.55 12.46 11.99 12.64 — — —
Bristol-Myers Squibb Co. — 39.45 33.97 27.33 24.42 13.51 10.89 13.68 16.16 19.56 27.48 23.10 28.87 24.60 20.23 19.09 19.79 — — —
Eli Lilly & Co. 32.66 22.98 25.58 24.82 27.08 23.37 23.99 38.43 33.99 37.45 47.62 25.86 39.61 33.07 29.23 32.37 25.63 — — —
Illumina Inc. 124.33 59.77 60.31 46.36 44.17 46.74 51.96 53.12 48.64 46.46 55.70 44.02 53.47 57.62 58.10 52.79 40.99 — — —
Johnson & Johnson 21.84 19.46 19.66 18.67 19.83 17.23 19.08 20.36 18.34 20.42 18.93 18.18 18.94 18.71 17.29 15.95 16.09 — — —
Merck & Co. Inc. 23.89 16.00 17.23 15.88 17.47 17.97 18.21 19.17 25.08 25.60 34.95 27.63 22.58 38.37 25.21 30.01 33.62 — — —
Pfizer Inc. 23.12 16.79 18.20 15.97 14.36 14.64 13.82 15.62 17.19 18.14 17.36 15.05 15.62 16.20 16.11 16.34 16.88 — — —
Regeneron Pharmaceuticals Inc. 14.82 20.36 23.98 26.60 19.01 16.21 15.41 14.44 17.53 16.43 18.75 14.23 16.71 23.63 29.60 32.24 28.70 — — —
Vertex Pharmaceuticals Inc. 19.16 20.35 33.91 40.27 51.98 64.96 52.36 56.45 74.57 66.84 442.93 — 331.55 1,018.05 112.83 99.84 2,143.58 — — —
Zoetis Inc. 35.22 36.65 36.24 28.78 35.00 30.23 32.11 27.78 22.59 23.98 23.28 21.51 22.33 21.75 20.64 20.42 18.65 — — —

Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).

1 Data adjusted for splits and stock dividends.

2 Q4 2020 Calculation
Operating profit per share = (Income (loss) from operationsQ4 2020 + Income (loss) from operationsQ3 2020 + Income (loss) from operationsQ2 2020 + Income (loss) from operationsQ1 2020) ÷ No. shares of common stock outstanding
= (2,651,000,000 + 2,001,000,000 + -2,983,000,000 + 2,402,000,000) ÷ 1,256,593,156 = 3.24

3 Closing price as at the filing date of Gilead Sciences Inc.’s Quarterly or Annual Report.

4 Q4 2020 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 62.79 ÷ 3.24 = 19.38

5 Click competitor name to see calculations.

Price to Sales (P/S)

Gilead Sciences Inc., historical P/S calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
No. shares of common stock outstanding1 1,256,593,156 1,253,528,149 1,253,724,370 1,254,373,400 1,263,636,656 1,265,145,612 1,266,455,481 1,271,554,672 1,275,510,558 1,293,619,612 1,296,340,593 1,300,260,832 1,309,967,781 1,306,268,996 1,305,926,217 1,306,728,398 1,307,066,900 1,317,456,071 1,319,658,489 1,331,821,506
Selected Financial Data (US$)
Product sales (in millions) 7,328  6,493  5,067  5,467  5,796  5,516  5,607  5,200  5,681  5,455  5,540  5,001  5,837  6,402  7,046  6,377  7,216  7,405  7,651  7,681 
Sales per share2 19.38 18.21 17.42 17.85 17.50 17.39 17.33 17.20 16.99 16.88 17.57 18.68 19.59 20.70 21.47 21.92 22.92 0.00 0.00 0.00
Share price1, 3 62.79 59.87 68.81 77.47 70.10 65.39 63.98 66.07 65.28 70.35 77.87 65.69 80.36 73.21 73.44 66.92 70.50 74.00 80.41 84.68
Valuation Ratio
P/S ratio4 3.24 3.29 3.95 4.34 4.00 3.76 3.69 3.84 3.84 4.17 4.43 3.52 4.10 3.54 3.42 3.05 3.08 — — —
Benchmarks
P/S Ratio, Competitors5
Abbott Laboratories 6.30 6.13 5.77 5.09 4.83 4.72 4.98 4.52 4.37 3.98 3.84 3.57 3.84 3.77 3.62 3.40 3.70 — — —
AbbVie Inc. 4.05 4.10 4.59 3.64 4.22 3.69 2.96 3.56 3.58 4.06 4.60 5.37 6.67 5.50 4.25 4.07 3.84 — — —
Amgen Inc. 5.64 5.33 6.30 5.96 6.03 5.61 5.00 4.78 5.22 5.56 5.65 5.27 5.82 5.85 5.85 5.48 5.65 — — —
Bristol-Myers Squibb Co. 3.16 3.66 3.97 4.45 5.52 3.87 3.11 3.21 3.67 3.64 4.38 4.04 5.02 4.85 4.40 4.59 4.72 — — —
Eli Lilly & Co. 8.06 5.41 6.26 6.36 6.03 4.67 4.67 4.80 5.15 4.62 4.34 3.85 3.71 4.11 4.16 4.18 4.18 — — —
Illumina Inc. 22.26 13.20 15.50 12.64 12.28 12.35 12.92 13.59 12.89 13.12 15.36 11.58 11.77 11.53 11.65 11.27 10.03 — — —
Johnson & Johnson 5.15 4.73 4.84 4.78 4.79 4.16 4.32 4.62 4.45 4.61 4.36 4.29 4.56 5.06 4.93 4.60 4.62 — — —
Merck & Co. Inc. 3.93 4.30 4.38 4.05 4.33 4.59 4.87 4.67 4.92 4.57 4.29 3.75 3.68 3.80 4.25 4.34 4.54 — — —
Pfizer Inc. 4.50 4.16 4.32 4.05 3.66 3.85 3.80 4.20 4.49 4.75 4.51 3.89 4.05 4.00 3.80 3.75 3.84 — — —
Regeneron Pharmaceuticals Inc. 6.24 7.62 8.31 8.10 5.34 4.79 4.56 5.11 6.62 6.08 6.92 5.20 5.92 8.09 9.56 9.27 7.86 — — —
Vertex Pharmaceuticals Inc. 8.82 9.04 13.11 13.71 14.95 13.89 13.34 13.54 15.54 14.96 17.14 16.47 16.42 16.47 18.23 14.60 12.51 — — —
Zoetis Inc. 11.84 12.42 12.09 9.42 11.00 9.37 9.57 8.35 7.03 7.92 7.88 7.10 7.18 6.40 5.85 5.83 5.31 — — —

Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).

1 Data adjusted for splits and stock dividends.

2 Q4 2020 Calculation
Sales per share = (Product salesQ4 2020 + Product salesQ3 2020 + Product salesQ2 2020 + Product salesQ1 2020) ÷ No. shares of common stock outstanding
= (7,328,000,000 + 6,493,000,000 + 5,067,000,000 + 5,467,000,000) ÷ 1,256,593,156 = 19.38

3 Closing price as at the filing date of Gilead Sciences Inc.’s Quarterly or Annual Report.

4 Q4 2020 Calculation
P/S ratio = Share price ÷ Sales per share
= 62.79 ÷ 19.38 = 3.24

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. Gilead Sciences Inc.’s P/S ratio decreased from Q2 2020 to Q3 2020 and from Q3 2020 to Q4 2020.

Price to Book Value (P/BV)

Gilead Sciences Inc., historical P/BV calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
No. shares of common stock outstanding1 1,256,593,156 1,253,528,149 1,253,724,370 1,254,373,400 1,263,636,656 1,265,145,612 1,266,455,481 1,271,554,672 1,275,510,558 1,293,619,612 1,296,340,593 1,300,260,832 1,309,967,781 1,306,268,996 1,305,926,217 1,306,728,398 1,307,066,900 1,317,456,071 1,319,658,489 1,331,821,506
Selected Financial Data (US$)
Total Gilead stockholders’ equity (in millions) 18,202  17,445  18,027  22,067  22,525  20,604  22,616  21,951  21,387  22,861  21,672  20,591  20,442  24,845  22,677  20,441  18,887  16,868  15,536  13,398 
Book value per share (BVPS)2 14.49 13.92 14.38 17.59 17.83 16.29 17.86 17.26 16.77 17.67 16.72 15.84 15.60 19.02 17.36 15.64 14.45 12.80 11.77 10.06
Share price1, 3 62.79 59.87 68.81 77.47 70.10 65.39 63.98 66.07 65.28 70.35 77.87 65.69 80.36 73.21 73.44 66.92 70.50 74.00 80.41 84.68
Valuation Ratio
P/BV ratio4 4.33 4.30 4.79 4.40 3.93 4.02 3.58 3.83 3.89 3.98 4.66 4.15 5.15 3.85 4.23 4.28 4.88 5.78 6.83 8.42
Benchmarks
P/BV Ratio, Competitors5
Abbott Laboratories 6.65 6.30 5.94 5.40 4.96 4.65 4.86 4.49 4.38 3.94 3.72 3.23 3.40 2.95 2.71 2.42 3.76 2.72 3.20 2.70
AbbVie Inc. 14.18 10.93 11.31 — — — — — — — — 44.74 36.95 22.43 18.89 21.33 21.24 14.80 19.21 21.77
Amgen Inc. 14.53 11.57 13.67 14.33 13.84 11.47 10.37 9.92 9.41 8.56 8.35 7.41 5.02 3.98 4.05 3.91 4.14 3.51 4.27 4.16
Bristol-Myers Squibb Co. 3.55 2.87 2.82 2.77 2.80 5.30 4.63 4.91 5.89 5.89 7.67 6.65 8.88 6.75 6.05 6.36 5.66 5.56 8.36 8.38
Eli Lilly & Co. 35.07 26.02 35.12 47.73 51.67 31.28 39.03 46.37 12.87 8.58 8.96 6.18 7.33 6.20 6.49 6.43 6.33 5.28 6.25 5.55
Illumina Inc. 15.36 9.09 11.38 9.70 9.43 9.62 10.16 11.58 11.43 12.15 14.64 11.30 11.79 10.48 10.67 10.71 10.95 9.03 11.90 10.48
Johnson & Johnson 6.72 5.93 6.19 6.46 6.61 5.84 5.78 6.39 6.08 5.81 5.60 5.34 5.79 5.08 4.98 4.72 4.72 4.30 4.68 4.34
Merck & Co. Inc. 7.46 6.97 7.47 7.43 7.83 7.87 7.82 7.31 7.79 5.88 5.44 4.54 4.30 3.96 4.31 4.35 4.51 3.78 4.01 3.42
Pfizer Inc. 2.98 3.10 3.31 3.16 3.00 3.14 3.42 3.84 3.80 3.55 3.44 2.80 2.98 3.45 3.41 3.37 3.40 3.21 3.40 3.19
Regeneron Pharmaceuticals Inc. 4.81 6.21 7.34 5.33 3.79 3.48 3.38 3.74 5.07 4.92 5.97 4.80 5.66 7.37 9.07 9.49 8.58 8.02 11.19 10.54
Vertex Pharmaceuticals Inc. 6.30 6.66 9.42 10.23 10.23 9.57 9.09 9.36 10.68 14.56 16.73 16.56 20.14 21.11 23.25 19.64 18.42 18.42 24.79 21.23
Zoetis Inc. 20.97 22.55 25.71 21.68 25.42 21.53 24.00 21.31 18.74 21.38 22.36 19.72 21.52 16.49 17.11 17.96 17.46 15.25 18.64 20.16

Based on: 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-25), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-26), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-06), 10-Q (filing date: 2018-05-09), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-10), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).

1 Data adjusted for splits and stock dividends.

2 Q4 2020 Calculation
BVPS = Total Gilead stockholders’ equity ÷ No. shares of common stock outstanding
= 18,202,000,000 ÷ 1,256,593,156 = 14.49

3 Closing price as at the filing date of Gilead Sciences Inc.’s Quarterly or Annual Report.

4 Q4 2020 Calculation
P/BV ratio = Share price ÷ BVPS
= 62.79 ÷ 14.49 = 4.33

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. Gilead Sciences Inc.’s P/BV ratio decreased from Q2 2020 to Q3 2020 but then slightly increased from Q3 2020 to Q4 2020.